show that the clinical phenotype is driven by both RASSF1A loss and the independently transcribed RASSF1C isoform, which promotes SRC activation, pseudo-EMT, and β-catenin/YAP1-dependent invasion of tumor cells. The gene discussed is SRC; the disease is neoplasm.